Survival since the start of the protocol (D1 cladribine/Ara-C). (A) Overall survival. (B) Survival according to DAS¹⁰  evolution. Good responders (DAS decrease >4 points) appeared to have a better outcome than poor responders (DAS decrease ≤4 points) (P < .04).